Comparison of Dopamine and Norepinephrine in Shock

To the Editor: The Sepsis Occurrence in Acutely Ill Patients (SOAP) II study, reported by De Backer and colleagues (March 4 issue), 1 is a major multicenter effort to find the elusive answer to the question of whether one vasopressor is superior to another as first-line therapy for patients with cir...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 362; no. 24; pp. 2328 - 2331
Main Author Romero, Carlos M
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 17.06.2010
Subjects
Anti-Bacterial Agents - therapeutic use
Cardiovascular disease
Clinical Protocols
Colleges & universities
Combined Modality Therapy
Dopamine
Dopamine - adverse effects
Dopamine - therapeutic use
Heart attacks
Humans
Norepinephrine - adverse effects
Norepinephrine - therapeutic use
Shock - drug therapy
Shock, Cardiogenic - drug therapy
Shock, Cardiogenic - mortality
Shock, Septic - therapy
Vasoconstrictor Agents - adverse effects
Vasoconstrictor Agents - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:To the Editor: The Sepsis Occurrence in Acutely Ill Patients (SOAP) II study, reported by De Backer and colleagues (March 4 issue), 1 is a major multicenter effort to find the elusive answer to the question of whether one vasopressor is superior to another as first-line therapy for patients with circulatory shock. The use of dopamine was associated with a greater number of adverse events in the overall population and an unexpected increase in the rate of death in the subgroup of patients with cardiogenic shock. As is known, patients in various states of circulatory shock have in common the need . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ObjectType-Feature-3
ObjectType-Article-4
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1003900